Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Fellow Finance Plc’s half year review 2021

FELLOW FINANCE PLC COMPANY ANNOUNCEMENT 27.8.2021 8:00 AMVolume of intermediated loans has recovered to a growth path and we will start building a new innovative digital banking business  1.1.−30.6.2021 summary · Turnover was 5.5 million euros (5.8), decrease of 5.3% · Profit of the reporting period was -0.1 million euros (-0.7) · EBIT was 0.5 million euros (-0.1) · EBIT margin was 9.7% (-0.9) · Earnings per share (EPS) was -0.01 euros (-0.10) · Intermediated loan volume was approximately 90.7 million euros (69.1) · Intermediated loan volume grew 31% compared to

Green Landscaping Group Interim Report January-June 2021

27 August 2021 - 07:00 CEST “Substantial increase in sales, earnings and cash flow” April-June 2021 · Sales during the quarter amounted to SEK 794.4 (552.1) million, which is an increase of 43.9 percent*. Organic growth was 2.8 percent. · EBITA amounted to SEK 65.1 (46.5) million. It corresponds to an increase of 40.0 percent. · EBITA margin amounted to SEK 8.2 (8.4) percent. · Cash flow from operating activities amounted to SEK 104.2 (63.0) million. · Net debt amounted to SEK 913.3 (518.5) million. · Earnings per share were SEK 0.76 (0.82). Diluted earnings per

Nordic Nanovector ASA: Resultat for andre kvartal og første halvår 2021

Oslo, Norge, 27. august 2021 Nordic Nanovector ASA (OSE:NANOV) publiserer i dag resultatene for andre kvartal og første halvår 2021. Selskapets ledelse vil presentere resultatene i en direktesendt webcast i dag kl. 08.30. En lenke til webcasten er tilgjengelig på www.nordicnanovector.com Resultatrapporten og presentasjonen er også tilgjengelig på selskapet nettside under fanen: www.nordicnanovector.com/Investors & Media/Reports and Presentation/Interim Reports/2021 Et opptak av webcastsendingen vil bli lagt ut på denne siden i etterkant av presentasjonen. «Nordic Nanovector

Aros Bostad’s Six Month Report for January-June 2021 shows continuous growth, listing of ordinary shares, strong sales and increased operating profit

Aros Bostadsutveckling AB publ (”Aros Bostad”) has published the six month report for January to June 2021. For Aros Bostad, the reporting period contained high activity and good sales in a strong residential market. During the second quarter, the company listed its ordinary shares at OMX Nasdaq First North, thereby enabling a higher pace in the development of wholly-owned residential development projects. Further, additional building rights were acquired during the second quarter and two development projects were divested as rental apartment projects to institutional investors after the

Ingrid welcomes Slöjd-Detaljer as a new client

We're excited to welcome Slöjd-Detaljer as our new client! Slöjd-Detaljer was founded in 1960 by Dan and Margit Medin. Back then, the main focus of the company was to provide schools with supplies for woodwork classes. Although the customer base, product range, catalogue and market has altered and expanded over the years, the basic business idea has remained unaltered—creativity and the joy of creating remains as Slöjd-Detaljer's core focus. By optimizing the delivery experience, Ingrid helps modern e-commerce companies turn a former pain point into a competitive advantage.

BAKKAFROST: Share Savings Plan Transaction

As a part of the share savings plan for employees in 2021, the following primary insiders have purchased Bakkafrost shares: · Regin Jacobsen, CEO, purchased 37 shares. After the transaction, he holds 4,617,264 shares. · Høgni Dahl Jakobsen, CFO, purchased 22 shares. After the transaction, he holds directly and indirectly 74,450 shares. · Odd Eliasen, Managing Director, purchased 60 shares. After the transaction, he holds 184,899 shares. · Annika Frederiksberg, Board Member, purchased 10 shares. After the transaction, she holds directly and indirectly 16,226 shares. The

SynAct Pharma Provides an Update on Patient Recruitment in the Phase 2a Clinical Trial of AP1189 in Rheumatoid Arthritis

SynAct Pharma AB (“SynAct”) today announced that recruitment in the BEGIN study in Rheumatoid Arthritis (RA) has been extended into the first half of September in order to reach the goal of 105 randomized patients, of which 98 have been recruited to date. As a result of the continued recruitment, reporting of key results previously expected to take place by the end of Q3 will be postponed to early Q4 after which a press release with top-line results will be released immediately. SynAct applauds the efforts of its clinical sites and their patients to keep this important evaluation of AP1189

Drones delivered defibrillators to patients with suspected cardiac arrests

Researchers at Karolinska Institutet in Sweden can now report the results of a unique pilot project where drones were used to deliver defibrillators to real-life alerts of suspected cardiac arrest. The drones were dispatched in more than a fifth of the emergencies and arrived on target and ahead of the ambulance in most cases. The results are published in the European Heart Journal and presented today at the European Society of Cardiology congress.”This is the first time in the world that a research group can report results from a study where drones flew defibrillators to location of real-

Dooba Finance AB (publ) – Publishing of the Quarter End Report for Q2 2021

On 27 October 2020, Dooba Finance AB (publ) (the “Company”) issued senior unsecured bonds in an amount of SEK 500.5 million guaranteed by Dooba Holdings Limited (the “Bonds”). On 22 March 2021, Dooba Finance AB (publ) (the “Company”) issued senior unsecured bonds in an amount of SEK 99 million under its existing framework of up to SEK 600 million senior unsecured bonds due 2024 (ISIN: NO0010895360) (the “Subsequent Bonds”).The Company today announces the publication of its Quarter End Report for Q2 2021. The report can be found at https://dfabbond.se/

Prostatype Genomics AB intends to carry out a directed share issue of approximately SEK 24 million

- Prostatype Genomics AB (“Prostatype” or “the Company”) hereby announces that the Company intends to carry out a directed share issue of approximately SEK 24 million to Swedish and international investors. The Company has assigned Sedermera Fondkommission to act as bookrunner in connection with the directed share issue. The capital raise is intended to finance activities carried out within the previously announced agreement with Proteomedix AG (“Proteomedix”).Cooperation with Proteomedix Proteomedix develops a next generation blood test for prostate cancer. The product complements

Prostatype Genomics AB enters into cooperation with leading actor in the prostate cancer area

– Agreement on marketing and R&D cooperation enhancing market position short- and long-termProstatype Genomics AB (“Prostatype Genomics”) has signed a cooperation agreement with Proteomedix AG (“Proteomedix”), a Zurich based science-driven company that has an approved product in the field of prostate cancer. The product is complementary to Prostatype®, the gene based prognostic tool developed and marketed by Prostatype Genomics. Used in different stages of the clinical process of prostate cancer, Prostatype® and the complementary product this will offer unique decision support for

Norway Royal Salmon ASA (NRS): Final result in mandatory offer to acquire all shares in Norway Royal Salmon ASA

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, INTO OR WITHIN AUSTRALIA, NEW ZEALAND, SOUTH AFRICA, HONG KONG, JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFULThis is a copy of the stock exchange announcement from NTS ASA of 26 August 2021 on ticker "NTS" Reference is made to the offer document dated 16 July 2021 (the "Offer Document") prepared in connection with the mandatory offer to purchase all remaining shares in Norway Royal Salmon ASA ("NRS") not already owned by NTS ASA (the “Offeror” or "NTS"),

Allocation of warrants to CEO and a key employee

Today, LED iBond International A/S’ board of directors has decided to issue warrants to its CEO and a key employee of the company’s subsidiary LED iBond A/S.The warrants are issued on the following terms: · 1,500 warrants are issued to the CEO of LED iBond International A/S and 1,000 warrants to the key employee of LED iBond A/S. · The warrants carry the right to subscribe for up to 50,000 new shares in the company at a nominal value of DKK 0.05 per share. · The warrants will vest over 24 months with 1/24 per month. · The strike price upon exercise is DKK 8.10 per share of DKK

Interim report for the second quarter and first half of 2021

Half-year revenue up 81 %, solid pipeline,revised financial outlook due to COVID-19Today, LED iBond International’s (LED iBond) Board of Directors approved the interim report for the second quarter (Q2) of 2021. Highlights of the report include: Business development · In general, LED iBond’s sales pipeline is solid and grows at a steady pace. · Vertical farming: The vertical farming market, in particular, is showing continued strong growth. LED iBond has received a substantial number of requests for proposals for lighting solutions for indoor farming projects. The company has

MUSTI GROUP PLC: Share Repurchase 26.8.2021

Musti Group Stock Exchange Release 26.8.2021 MUSTI GROUP PLC: Share Repurchase 26.8.2021 In the NASDAQ OMX Helsinki Trade date           26.8.2021Bourse trade         BuyShare                  MUSTIAmount             7 000 SharesAverage price/ share    33,9641 EURTotal cost            237 748,70 EUR Company now holds a total of 244 000 sharesincluding the shares repurchased on 26.8.2021 On behalf of Musti Group Nordea Bank Finland Plc Janne Sarvikivi

ODI Pharma AB: Publication of year-end report for the financial year 2020/2021

ODI Pharma AB (“ODI” or the “Company”) hereby publishes its year-end report for the fourth quarter and financial year 1[st] of July 2020 – 30[th] of June 2021. The report is available as an attached document to this press release and on the Company’s website (www.odipharma.com). Below is a summary of the report.Fourth quarter (2021-04-01 – 2021-06-30) The Group's net sales amounted to SEK 0 (-218 520). The Group's loss after financial items amounted to SEK -1,886,158 (-1,229,862). Result per share amounted to SEK -0.12 (-0.08).* The solidity as of 2021-06-30 was 96.55 % (96.23).*

Publication of a Prospectus

26 August 2021 International Personal Finance plc Publication of Prospectus The following prospectus (the "Prospectus") has been approved by the Financial Conduct Authority and is available for viewing: Prospectus dated 26 August 2021 relating to the International Personal Finance plc's €1,000,000,000 Euro Medium Term Note Programme. To view the full document together with the documents incorporated by reference, please paste the following URL into the address bar of your browser: http://www.ipfin.co.uk/en/investors/debt-funding-information.html A copy of the above

Norway Royal Salmon ASA (NRS): Flagging

Reference is made to NTS ASA's («NTS») mandatory bid for all outstanding shares in Norway Royal Salomon ASA («NRS»). On 26 August 2021, Norway Fresh AS accepted the offer of NOK 240 per share, and thus sells its 4,496,708 shares in NRS. This corresponds to 10.32% of the issued shares and votes in NRS. Following the transaction, Norway Fresh AS will no longer have ownership or voting rights in NRS. The flagging is triggered because Norway Fresh AS accepts NTS's mandatory offer, and thus Norway Fresh's ownership falls below 10%.

Ji Ham New Acting CEO of EG7

The Board of Enad Global 7 AB (publ) and Robin Flodin have agreed that effective immediately Robin will transition away from his current role as CEO of EG7 and will be replaced by the current CEO of Daybreak Game Company, EG7’s largest subsidiary, Ji Ham. During this transition Robin will stay on for six months to assist Ji as he assumes his new role within the EG7 family of companies. Ji will be appointed acting CEO of EG7 as a search for a permanent CEO has been initiated. Ji has an extensive background in both gaming and finance and has for the last six years been the CEO of Daybreak.

ALEXANDRIA PANKKIIRILIIKE OYJ: ACQUISITION OF OWN SHARES 26.08.2021

ALEXANDRIA PANKKIIRILIIKE OYJ NOTIFICATION 26.08.2021 at 18:30 CEST ALEXANDRIA PANKKIIRILIIKE OYJ: ACQUISITION OF OWN SHARES 26.08.2021 Date 26.08.2021Exchange transaction BuyShare class ALEXAmount 1,677Average price/share 8.5981 EURHighest price/share 8.6300 EURLowest price/share 8.5900 EURTotal price 14,419.01 EUR The shares held by Alexandria Pankkiiriliike Oyj on 26.08.2021: ALEX 1,677 On behalf of Alexandria Pankkiiriliike Oyj  Skandinaviska Enskilda Banken AB (Publ)

Nomination Committee ahead of RevolutionRace’s Annual General Meeting 2021

At the Extraordinary General Meeting of RVRC Holding AB (publ) on 15 April 2021, it was resolved that the Nomination Committee of the company ahead of the Annual General Meeting 2021 shall be composed of the representatives of the three largest shareholders in terms of voting rights, as of the last banking day in July 2021, and of the Chairman of the Board of Directors.Following contacts with the company's shareholders, the following members have been appointed to form, together with the Chairman of the Board, a Nomination Committee for the time until a new Nomination Committee has been

BerGenBio ASA: Share capital increase

Bergen, Norway, 26 August 2021 - Reference is made to the stock exchange notice published by BerGenBio ASA (the "Company") (OSE: BGBIO) on 23 August 2021 where the Company announced that the board of directors of the Company had resolved to increase the Company's share capital in connection with the exercise of options pursuant to the Company's share option program. A total of 270,000 options were exercised and 270,000 new shares were issued at an average subscription price of NOK 10.86 per share. The share capital increase has been duly registered in the Norwegian Register of Business

There are no items matching the current filter
There are no more items matching the current filter
Back to top